Compounds > irinotecan
Page last updated: 2024-08-24

irinotecan and buparlisib

irinotecan has been researched along with buparlisib in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bachmann, E; Galle, PR; Khillimberger, K; Linnig, M; Moehler, M; Mueller, A; Schimanski, CC1
Boukouris, AE; Buitrago-Molina, LE; Hegermann, J; Kirstein, MM; Kühnel, F; Manns, MP; Marhenke, S; Orlik, J; Pothiraju, D; Schütt, J; Vogel, A1
Atis, S; Combès, E; Del Rio, M; Gabanou, M; Gongora, C; Jarlier, M; Larbouret, C; Martineau, P; Mollevi, C; Pérez-Gracia, E; Torro, A; Tosi, D; Vié, N1

Other Studies

3 other study(ies) available for irinotecan and buparlisib

ArticleYear
Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:6

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Caspase 3; Cell Cycle Checkpoints; Cell Survival; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; HCT116 Cells; HT29 Cells; Humans; Imidazoles; Irinotecan; Morpholines; Mutation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases

2012
Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2013, Volume: 33, Issue:5

    Topics: Aminopyridines; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Camptothecin; Carcinoma, Hepatocellular; Cell Cycle; Cell Line; Cell Respiration; Cisplatin; Doxorubicin; Everolimus; Humans; Imidazoles; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Liver Neoplasms; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Sirolimus; TOR Serine-Threonine Kinases

2013
Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment.
    BMC cancer, 2018, Aug-13, Volume: 18, Issue:1

    Topics: Aminopyridines; Animals; Benzimidazoles; Camptothecin; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; HT29 Cells; Humans; Irinotecan; MAP Kinase Kinase 1; Mice; Molecular Targeted Therapy; Morpholines; Protein Kinase Inhibitors; Signal Transduction; Xenograft Model Antitumor Assays

2018